Home › Companies › FATE
Fate Therapeutics
Market cap $124M 121.6M shares (10-Q, Oct 30, 2026) × $1.02 close Nov 17, 2026
Most recent annual filing: 2026-02-26
Q3Q4Q1 ’27Q2Q3Q4Q1 ’28Q2
- FT839 Ph1 start2H 2026FT839 Ph1 start, 2H 2026, routine
- Autolus obe-cel CARLYSLE readout4Q 2026Autolus obe-cel CARLYSLE readout, 4Q 2026, material
- Kyverna miv-cel BLA filing4Q 2026Kyverna miv-cel BLA filing, 4Q 2026, notable
- FATE corporate updateNov 2026FATE corporate update, Nov 2026, routine
- FATE financing~Nov 2026FATE financing, ~Nov 2026, routine
- FT836 readout1H 2027FT836 readout, 1H 2027, notable
- FT819 interim2H 2027FT819 interim, 2H 2027, material
- FT819 enrollment done1H 2028FT819 enrollment done, 1H 2028, notable
- Autolus obe-cel LUMINA readout2028Autolus obe-cel LUMINA readout, 2028, notable
- FT819 toplinemid-2028FT819 topline, mid-2028, major
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a
six-month window. Deeper blue means more of the thesis rides on the event; it is not a
view on the stock.
Pipeline (10 active programs)
FT819
FT836
FT825
ONO-8250
FT522
FT839
Technology platforms
Discontinued (1)
- FT522 — B-Cell Lymphoma · Phase 1 study in relapsed/refractory BCL completed enrollment; further development being evaluated in autoimmune indications
Capital (as filed)
- Cash
- $43.9M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $95.2M Sep 30, 2026
- Operating cash flow
- −$27.8M quarter to Sep 30, 2026 (10-Q)
- As stated in coverage
- $139M cash, runway mid-2028 per the update of Nov 5, 2026 — the company's own words as read there, not the filed figure
Offering documents (2)
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (4)
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (4 calls)
Every verdict Biotech Distilled has published on Fate Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-09-25 Watch Fate Therapeutics (FATE) — Scientific Deep Dive for FT819, FT839 and Pipeline Products Fate has solved iPSC manufacturing and FT819 has a strong safety profile, but the pivotal regimen's complete renal response rate is undisclosed, the trial reads out after the cash, and the regulatory bar is unwritten.
- 2026-10-27 Watch UPDATE: Fate Therapeutics (FATE) - The Denominator Arrives, Wearing a Disguise ASN data provided a denominator but pooled CRR and PERR on only n=2 pivotal-regimen patients, which is insufficient to de-risk the efficacy question or justify buying ahead of a likely dilutive financing.
- 2026-11-06 Watch UPDATE: Fate Therapeutics (FATE) - The Tap Is Open Q3 revealed quiet ATM sales and a new $100M Leerink ATM with runway leaning on an unsigned CIRM grant; the pivotal CRR count is still missing and ACR is the defined test.
- 2026-11-11 Avoid UPDATE: Fate Therapeutics (FATE) - The Trigger Trips ACR repeated the same pooled August renal numbers for the third straight venue without a CRR-only count at the pivotal regimen, tripping the author's pre-stated PASS trigger, while a continuous ATM now overhangs the stock.
- Avoid call · opened Nov 11, 2026 at $1.61 · -36.6% vs XBI -7.1% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Filings & releases (23)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first.
Releases captured from Sep 25, 2026;
filings from March 2026.
Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 12, 2026424B5Prospectus supplement (offering)
- Nov 10, 2026ReleaseFate Therapeutics Presents New FT819 Data At ACR Convergence 2026 Highlighting Meaningful Clinical Responses In Lupus Without The Use Of Conditioning Chemotherapy→ BD updateACR delivered encouraging no-conditioning responses in extrarenal lupus — but the pivotal-regimen CRR count at 900M + bendamustine is still missing, triggering the PASS condition I named explicitly in both the deep dive and my November 5 update.
- Nov 9, 2026SCHEDULE 13D/A13D amendment
- Nov 5, 2026S-3Shelf registration→ BD updateSummary on the 8-K
- Nov 5, 2026ReleaseFate Therapeutics Reports Third Quarter 2026 Financial Results And Business Updates→ BD updateSummary on the 8-K
- Nov 5, 20268-KCurrent report: material agreement, agreement terminated→ BD updateFate's Q3 print confirms the raise I said was inevitable has begun — a fresh $100M ATM with Leerink is live, cash sits at $139.1M (plus a $15M CIRM grant), and the runway guidance nudges to mid-2028; now we know exactly what the dilution trap looks like.
- Nov 5, 20268-KCurrent report: results of operations · EX-99.1→ BD updateSummary on the 8-K
- Nov 5, 2026424B5Prospectus supplement (offering)→ BD updateSummary on the 8-K
- Nov 5, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Oct 26, 2026ReleaseFate Therapeutics Presents Updated Preliminary Data For FT819 In Active Lupus Nephritis At American Society Of Nephrology Kidney Week 2026→ BD updateFate finally published the renal-response count the prior writeup said had gone silent — 100% CRR/PERR at Month 6 in the RECLAIM-LN bendamustine regimen — but the denominator is still only n=2, and the stock has drifted lower since the deep dive. Here's what the data actually say.BD extracted 1 program update from this document → FATE pipeline
- Oct 12, 2026ReleaseFate Therapeutics Appoints Jamie Harrell As Senior Vice President, Market Development & Commercial Operations To Lead The Commercialization Of CAR T-Cell Therapies
- Oct 1, 2026ReleaseFate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferencesvia aggregator
- Sep 28, 20268-KCurrent report: other events · EX-99.1
- Sep 25, 2026ReleaseFate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LNvia aggregator
- Aug 13, 20268-KCurrent report: results of operations · EX-99.1
- Aug 13, 202610-QQuarterly report
- Jun 15, 20268-KCurrent report: officer / director change, shareholder vote
- Jun 4, 20268-KCurrent report: other events · EX-99.1
- May 13, 20268-KCurrent report: results of operations · EX-99.1
- May 13, 202610-QQuarterly report
- Apr 24, 2026DEFA14AProxy soliciting material
- Apr 24, 2026DEF 14AProxy statement
- Apr 22, 2026SCHEDULE 13D/A13D amendment
5 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)